Leo Wang, MD
Neurology · Seattle, WANPI 1124150156
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $33,680 of the $37,433 with a category attached, or 90.0%. 10 manufacturers reported payments, led by Sarepta Therapeutics, Inc. at 34.4% of the total. Reporting peaked in 2024 at $17,181 and has fallen 74.4% since, to $4,395 in 2025. Among neurology clinicians in WA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 34 payments — averaging $1100.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sarepta Therapeutics, Inc.$13K
- Mitsubishi Tanabe Pharma Development America, Inc.$6K
- CSL Behring$4K
- Argenx US, Inc.$4K
- Lupin Inc.$3K
- Biogen$2K
- plus $5K from 4 others
Across 27 payments — averaging $12,022 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Argenx US, Inc.$167K
- Biogen$108K
- Harmony Biosciences LLC$49K
What the payments were for
- Consulting fees$33,68090%
- Speaking & faculty fees$1,3504%
- Travel & lodging$1,6134%
- Food & beverage$7752%
- Education$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sarepta Therapeutics, Inc. | 9 | $12,861 |
| Mitsubishi Tanabe Pharma Development America, Inc. | 3 | $5,750 |
| CSL Behring | 6 | $4,456 |
| Argenx US, Inc. | 5 | $4,423 |
| Lupin Inc. | 1 | $2,815 |
| Biogen | 2 | $2,133 |
| UCB, Inc. | 4 | $1,761 |
| Amylyx Pharmaceuticals, Inc. | 1 | $1,350 |
| Vertex | 2 | $1,043 |
| AstraZeneca | 1 | $840 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$37,433 in reported general payments places this provider in the 90th percentile of 418 neurology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Radicava OrsEdaravone | 56 | $784,835 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 14 | $345,871 |
| NuedextaDextromethorphan Hbr/Quinidine | 23 | $35,320 |
| Riluzole | 35 | $5,273 |
| Glycopyrrolate | 13 | $2,549 |
| Mexiletine Hcl | 25 | $792 |
| Morphine Sulfate ErMorphine Sulfate | 11 | $221 |
| Amitriptyline Hcl | 25 | $130 |
Paid to pharmacies, not to this prescriber.
Other neurology in Seattle
- Pavle RepovicSeattle$1.1M
- Nathaniel WatsonSeattle$486K
- Christyn EdmundsonSeattle$318K
- Pravin KhemaniSeattle$194K
- Mariko KitaSeattle$186K
- Michael RosenbloomSeattle$179K
- Michael WeissSeattle$103K
- Sylvia LucasSeattle$90K
- Shuvro RoySeattle$46K
- Lucas McCarthySeattle$40K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.